drugset / Trial / NCT02496988
Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas
Non-randomizedParallel-groupOpen-label
Summary
The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.
Timeline
- Start
- 2015-07
- Primary completion
- 2028-07
- Completion
- 2030-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |
| Subject | cytokine-induced killer cells | Cell therapy | — | Intravenous |